Interstitial Lung Abnormalities Are Associated with Acute Respiratory Distress Syndrome
To the Editor:
Interstitial lung abnormalities are specific densities on chest computed tomography (CT) scans that have been identified in research participants without a clinical diagnosis of interstitial lung disease (ILD) (1) . Interstitial lung abnormalities have been associated with decreased measures of pulmonary function and 6-minute-walk distance, increased respiratory symptoms, and genetic abnormalities, suggesting they may represent an early or mild form of pulmonary fibrosis (1). They have also recently been associated with an increased risk of death, specifically, death from respiratory failure (2) .
Patients with fibrotic lung disease can develop acute respiratory failure due to an exacerbation of their underlying disease. These acute exacerbations are characterized pathologically by diffuse alveolar damage (3) , which is also the most common pathologic finding in acute respiratory distress syndrome (ARDS) (4, 5) . Given the radiologic and pathologic similarities between exacerbations of fibrotic lung disease and ARDS, and to further explore the increased risk of death from respiratory failure associated with interstitial lung abnormalities, we sought to determine whether interstitial lung abnormalities on prior CT imaging were associated with an increased risk of ARDS, in a cohort of patients with sepsis or the systemic inflammatory response syndrome (SIRS). Some of the results have been previously reported in the form of an abstract (6) .
Methods
We performed a nested, prospective cohort study using participants from the Institutional Review Board-approved Registry of Critical Illness at Brigham and Women's Hospital (Boston, MA) (7). All participants screened, consented, and enrolled between September 2008 and February 2015 were included in the analysis if they had sepsis or SIRS. ARDS was defined using the Berlin definition (4) for cases after 2012 and the American-European Consensus Conference (AECC) definition (8) for cases before 2012; ARDS was either present on admission or developed within 7 days of intensive care unit (ICU) admission.
Chest CT scans were reviewed if performed at least 7 days before ICU admission; images were reviewed by up to three readers (one pulmonologist and two radiologists) using a previously described sequential reading method (1) . Interstitial lung abnormalities were defined as nondependent changes affecting more than 5% of any lung zone, including ground-glass or reticular abnormalities, diffuse centrilobular nodularity, nonemphysematous cysts, honeycombing, or traction bronchiectasis (1, 2) ( Figures 1A1  and 1A2 ). Indeterminate scans were those with focal or unilateral abnormalities (,5% of the lung).
Association analyses between pairs of variables were conducted with Fisher's exact tests (for categorical variables) and two-tailed t tests (for continuous variables). Logistic regression models were used to evaluate the association between interstitial lung abnormalities and ARDS and the association between interstitial lung abnormalities and 28-day mortality. Stepwise selection was used to build multivariable regression models. In primary analyses, patients with a history of ILD were excluded. All P values reported are two sided, and a level of 0.05 was considered statistically significant. SAS version 9.4 (SAS Institute, Cary, NC) was used for analyses.
Results
Baseline characteristics of patients stratified by presence of CT imaging and interstitial lung abnormality status are presented in Table 1 . Participants with prior CT imaging were more likely to have a history of malignancy and respiratory disease. Interstitial lung abnormalities were present in 8% (n = 19) of patients with a prior CT Chest computed tomography (CT) and pathology images from a patient with interstitial lung abnormalities and subsequent acute respiratory distress syndrome (ARDS). Representative axial images from the CT scans of a participant with interstitial lung abnormalities on chest CT (A1 and A2, arrows demonstrating subpleural reticular changes and, in A1, honeycombing) before the development of ARDS (B1 and B2). A1 and B1 are above the carina, and A2 and B2 are at the level of the right inferior pulmonary vein. The chest CT before ARDS was done for follow-up of a tracheal tumor. At the time of admission to the intensive care unit, the changes seen on the prior CT scan were largely obscured on repeat imaging, and the patient's presentation was believed to be consistent with ARDS. C is a low-power view of a lung section at the time of autopsy performed on this patient, showing both diffuse alveolar damage (C1 arrow) and evidence of underlying fibrosis (C2 arrow). (Tables 1 and 2 ). Similar results were seen when additionally adjusting for history of respiratory disease and malignancy (OR, 4.5; 95% CI, 2.2-9.0; P , 0.0001), when the cohort was narrowed to patients with sepsis alone (OR, 3.9; 95% CI, 2.0-7.9; P = 0.0001), when patients with a history of ILD were included (OR, 2.9; 95% CI, 1.7-4.9; P , 0.0001), and when compared with both those without interstitial abnormalities and with indeterminate status (OR, 15.8; 95% CI, 4.3-58.4; P , 0.0001).
Interstitial abnormalities were also associated with an increased risk of 28-day mortality. After adjusting for age and APACHE score, patients with interstitial lung abnormalities had increased odds of death compared with those without interstitial abnormalities (OR, 2.3; 95% CI, 1.2-4.2; P = 0.01). A similar, but nonstatistically significant, association between interstitial lung abnormalities and death was noted when limited to patients with ARDS (OR, 2.4; 95% CI, 0.9-6.5; P = 0.08).
Discussion
The central finding of this study is that, in a cohort of critically ill patients with sepsis and SIRS, patients with interstitial lung abnormalities were significantly more likely to develop ARDS. In addition, after adjustment for age and APACHE score, patients with interstitial lung abnormalities were more likely to die within 28 days after ICU admission.
The criteria in both the AECC and Berlin definitions of ARDS are nonspecific, which has led to concerns that these definitions may incorporate a variety of conditions that may mimic ARDS (9, 10), including exacerbations of fibrotic lung disease. Neither the AECC nor the Berlin definition specifically recommends review of prior imaging when diagnosing ARDS. Although it has recently been reported that interstitial lung abnormalities are associated with an increased risk of death, specifically from respiratory failure (2) , larger studies will be needed to determine how often interstitial lung abnormalities precede a diagnosis of ARDS and how often unselected patients with ARDS have evidence for antecedent interstitial lung abnormalities.
This study has a number of important limitations. First, although our findings demonstrate an association between interstitial lung abnormalities and ARDS in patients with a prior clinically indicated CT scan, given the differences in baseline characteristics and outcomes in those without a prior CT scan, we urge caution in extrapolating our findings to patients with ARDS more broadly. Second, we cannot comment about whether these findings apply to patients who did not consent to enroll in the Registry of Critical Illness. Third, small sample size may have limited the statistical power to detect an association between interstitial lung abnormalities and mortality in patients with ARDS.
Our findings suggest that cohorts of patients with sepsis and SIRS may contain patients with undiagnosed interstitial lung abnormalities, and raise the possibility that interstitial lung abnormalities may mimic, or in some cases be a risk factor for, ARDS. n 2.1 (0.9-4.9) 0.1 2.4 (0.9-6.5) 0.08
Definition of abbreviations: ARDS = acute respiratory distress syndrome; CI = confidence interval; ILA = interstitial lung abnormalities; OR = odds ratio.
Lysyl Oxidase Inhibition by Heparin in Idiopathic Pulmonary Fibrosis: Is There Still Hope?
To the Editor:
There is currently a lively debate going on in the Journal about the safety of vitamin K antagonists (VKAs) in patients with idiopathic pulmonary fibrosis (IPF) requiring anticoagulation (1, 2), because treatment with VKAs in the ACE-IPF (Anticoagulant Effectiveness in IPF) study was associated with increased mortality in patients with IPF with no (other) indication for anticoagulation (3). The ACE-IPF trial was conducted because the coagulation cascade might be implicated in the pathogenesis of lung fibrosis, and a previous Japanese study had suggested anticoagulant therapy to have a favorable effect on survival in patients with IPF (3, 4). The fundamental difference between both anticoagulation trials was that patients with IPF in the Japanese anticoagulant study used VKAs in an outpatient setting and low-molecular-weight heparin (LMWH) during hospitalizations, whereas those in the ACE-IPF study used warfarin once daily and no LMWH, irrespective of whether or not they were hospitalized (3, 4) . Recently, I suggested that LMWH might be the ideal replacement of VKAs in patients with IPF (2) because heparins inhibit the enzyme lysyl oxidase (LOX) (5) . I regard LOX inhibition as a therapy target with great potential in IPF. However, on January 5, 2016, the biopharmaceutical company Gilead Sciences Inc. issued a press release announcing the termination of their phase 2 trial assessing the effects of LOX2 inhibitor simtuzumab on disease progression in patients with IPF (6) . The Data Monitoring Committee recommended this early ending on the basis of the lack of a treatment benefit in patients randomized to receive the monoclonal antibody. I do not completely discard the concept of LOX inhibition by heparin in IPF, despite the negative results with simtuzumab.
IPF is characterized by the excessive accumulation of proteins in the extracellular matrix (ECM). Elastin is a protein in the ECM that confers elasticity and resilience to dynamic organs such as the lungs, whereas collagen is mainly responsible for tensile strength. Procollagen and tropoelastin are the precursors of collagen and elastin, respectively. After the early postnatal period, formation of new elastin is suppressed at a post-transcriptional level. Elastogenesis, however, can be reactivated after tissue injuries, such as ECM degradation (Figure 1 ). After synthesis, procollagen and tropoelastin are aligned with many other monomers into polymers, and polymers are subsequently crosslinked by LOX into mature collagen and elastin fibers. This crosslinking gives rise to the amino acids hydroxyproline, which is a major component of collagen, and desmosine, which only occurs in elastin fibers. Crosslinked polymers are relatively resistant to proteases, whereas uncrosslinked fibers are extremely vulnerable to enzymatic degradation (7) . LOX inhibition will therefore ameliorate the accumulation of mature collagen and elastin fibers in the ECM and promote elastolysis (7) . Preventing collagen crosslinking may have a theoretical benefit in IPF, whereas the prevention of elastin crosslinking does not. In the same press release, Gilead also reported that the Data Monitoring Committee recommended the continuation of the phase 2 studies in nonalcoholic steatohepatitis and primary sclerosing cholangitis, suggesting a more favorable effect of simtuzumab in these hepatic diseases. I believe it is conceivable that the inhibition of elastin crosslinking by simtuzumab does not cause major problems in a rigid organ like the liver-where elasticity and resilience are at most of minor importance to its functions-whereas it may do so in dynamic ones, such as the lungs, where crosslinked elastin is a basic requirement to provide elasticity and resilience for proper ventilation.
In contrast to simtuzumab, heparin only prevents the crosslinking of procollagen fibers and does not affect tropoelastin crosslinking (5) . I believe that the selective inhibition of collagen crosslinking has great potential in IPF. A previous study has shown in a bleomycin lung fibrosis model that the coadministration of nebulized heparin ameliorated the formation of fibrosis and suppressed hydroxyproline formation (8) . I suggest that heparinbesides other effects that might theoretically ameliorate the progression of lung fibrosis, such as suppressing the coagulation cascade-inhibited LOX in these rabbits, leading to a marked reduction of collagen crosslinking and collagen accumulation (4, 8) . Inhaled heparin has been tested in patients with IPF and appeared to be safe and well tolerated, but its disease-modifying effects were not assessed in this study (9) .
That is why I believe that-despite the disappointment regarding simtuzumab-there is still hope for LOX inhibition by heparin in IPF, and a clinical trial should be established to study
